Nuvectis Pharma (NVCT) investor relations material

Executive summary

• Focused on developing precision oncology medicines, with lead candidate NXP900 advancing through Phase 1b monotherapy and combination studies, and NXP800's future under evaluation after anti-cancer activity in ovarian cancer.

• Completed Phase 1a dose escalation and drug-drug interaction studies for NXP900, supporting once-daily oral dosing and combination therapy.

• Presented emerging clinical data at a major oncology conference, reinforcing biomarker-based patient selection.

• No revenue generated to date; operations funded by equity and public offerings.

Financial highlights

• Cash and cash equivalents were $35.4 million as of September 30, 2025, up from $18.5 million at December 31, 2024, mainly due to public offering and ATM facility usage.

• Net loss for Q3 2025 was $7.5 million, compared to $4.2 million in Q3 2024, driven by milestone and clinical study expenses.

• Research and development expenses increased to $5.8 million in Q3 2025, mainly due to a $2.0 million license fee and higher clinical expenses.

• General and administrative expenses rose to $2.0 million in Q3 2025, driven by higher professional and consulting fees.

• Net cash used in operating activities for the nine months ended September 30, 2025, was $12.0 million; net cash provided by financing activities was $28.9 million.

Outlook and guidance

• Cash runway expected to support operations into the third quarter of 2027.

• Additional capital will be required to complete clinical trials, obtain regulatory approvals, and commercialize product candidates.

• Expenses are expected to increase as clinical development progresses and as public company operations expand.